About Us
Our Company
Overview
Management Team
Board of Directors
Scientific Advisory Board
Partners & Collaborations
Contact
Our Pipeline
Pipeline
Overview
Azenosertib
ZN-d5
Clinical Trials
Our Approach
Integrated Discovery Engine
Our advanced approach to efficiently identifying and developing novel oncology therapies.
Supporting Publications
Investors & Media
Investors & Media
Investor Home
News & Events
Press Releases
Events & Presentations
Stock Information
Stock Quote & Chart
Historic Price Lookup
Investment Calculator
Analyst Coverage
Financials & Filings
SEC Filings
Corporate Governance
Documents & Charters
Management Team
Board of Directors
Scientific Advisory Committee
Committee Composition
Investor Resources
Investor FAQs
Email Alerts
Investor Contact
Careers
Working at Zentalis
Be part of a vibrant team committed to our common goal: to better the lives of patients impacted by cancer.
Job Opportunities
Clinical Trials
Zentalis Pharmaceuticals is conducting clinical studies evaluating its small molecule therapeutics. To learn more about our ongoing clinical trials, please visit
www.clinicaltrials.gov
.
Ongoing Clinical Trials
Azenosertib
DENALI: Phase 2 Monotherapy Study in Cyclin E1 Driven High Grade Serous Ovarian Cancer
TETON: Phase 2 Monotherapy Study in Uterine Serous Carcinoma
MAMMOTH: Phase 2 Combination Study of Azenosertib and PARPi in PARP Resistant Ovarian Cancer
Phase 1b/2 Combination Study of Azenosertib and Chemotherapy in Ovarian Cancer
Phase 1 Monotherapy, Dose Optimization Study in Solid Tumors
Phase 1/2 Combination Study of Azenosertib and Gemcitabine in Osteosarcoma
Phase 1/2 Combination Study of Azenosertib and BEACON Regime in Metastatic Colorectal Cancer
ZN-d5
Phase 1/2 Monotherapy Study in Relapsed or Refractory Light Chain (AL) Amyloidosis
Phase 1/2 Combination Study of ZN-d5 and Azenosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
Phase 1 Monotherapy Study in Non-Hodgkin’s Lymphoma (NHL)
